Is the HCV pipeline heading in the right direction?

Gastroenterology

Volumn 144, Issue 3, 2013, Pages 482-485

  Aronsohn, Andrew ^a   Muir, Andrew J ^b   Swan, Tracy ^c   Jensen, Donald ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; ASUNAPREVIR; BI 207127; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; FALDAPREVIR; GS 5885; INTERLEUKIN 28B; PEGINTERFERON LAMBDA; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; NOTE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 84874086941     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.01.018     Document Type: Editorial

References (21)

1. F. Poordad, J. McCone Jr, B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
2. I.M. Jacobson, J.G. McHutchison, G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
4. F. Kanwal, T. Hoang, J.R. Kramer Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection Gastroenterology 140 2011 1182 1188e1
5. C. Hezode, C. Dorival, F. Zoulim Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting) 2012 American Association for the Study of Liver Diseases Boston
6. M.S. Sulkowski Hepatitis C virus-human immunodeficiency virus coinfection Liver Int 32 Suppl 1 2012 129 134
7. D.T. Dieterich, V. Soriano, K.E. Sherman Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis 2012 Conference on Retroviruses and Opportunistic Infections Seattle, WA
8. M.S. Sulkowski, S. Pol, C. Cooper Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients 2012 Conference on Retroviruses and Opportunistic Infections Seattle, WA
9. N. Chalasani, C. Manzarbeitia, P. Ferenci Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials Hepatology 41 2005 289 298
10. V. Garg, R. van Heeswijk, J.E. Lee Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
11. F. Fabrizi, B. Takkouche, G. Lunghi The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies J Viral Hepat 14 2007 697 703
12. M.G. Ghany, D.R. Nelson, D.B. Strader An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
13. M. Fried, M. Buti, G. Dore TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study (TMC435-C205) 2011 AASLD San Francisco
14. M.S. Sulkowski, P. Asselah, P. Ferenci Treatment with the 2nd generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates: results from SILEN-C1 in treatment-naïve patients across different baseline factors 2011 AASLD San Francisco
15. S. Zeuzem, V. Soriano, P. Asselah Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 ± ribavirin (R): final results of SOUND-C2 and predictors of response 2012 AASLD Boston
16. C. Hezode, G. Hirschfield, W. Ghesquire Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results 2012 AASLD Boston
17. A. Lok, D. Gardiner, C. Hezode Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) 2012 AASLD Boston
18. E. Lawitz, J. Lalezari, T. Hassanein PROTON: PSI-7977 & Peg/RBV in treatment-naïve patients with HCV GT1: sustained virologic response 2011 AASLD San Francisco
19. E. Gane, C.A. Stedman, R. Hyland PSI-7977: ELECTRON interferon is not required for sustained virologic response in treatment-naïve patients with HCV GT2 or GT3 2011 AASLD San Francisco
20. G. Everson, E. Lawitz, A. Thompson The NS5A inhibitor GS-5885 is safe and well tolerated in more than 1000 patients treated in phase 2 studies 2012 AASLD Boston
21. K. Kowdly, E. Lawitz, F. Poordad A 12-week interferon-free treatment regimen with ABT-450/r, ABT 267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection 2012 AASLD Boston